In connection with the recently announced reduction in workforce and change in corporate strategy, Pardes Biosciences, Inc. and Brian P. Kearney, PharmD, the Company's Chief Development Officer, have agreed that Dr. Kearney's employment with the Company will terminate effective as of May 15, 2023.
Pardes Biosciences, Inc.
Equities
PRDS
US69945Q1058
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.84% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |